Biomarker Establishment for Superior Treatment of PTSD

PTSD Clinical Trial

Official title:

Biomarker Establishment for Superior Treatment of PTSD

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03343028
• Other study ID #: 39006
• Status: Completed
• Start date: September 2016
• Est. completion date: September 30, 2019

Study information

• Verified date: February 2020
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of Biomarker Establishment for Superior Treatment of PTSD is to accelerate research on the discovery of biological, neurological and neuroimaging markers for Post- Traumatic Stress Disorder (PTSD). The investigators hope to validate and extend the network efficiency and verbal memory biomarker for PTSD. The investigators hope to learn whether there are pretreatment biological factors that can predict response to therapy. They want to do this by understanding the brain network function, relating EEG to functional magnetic resonance imaging, and application of network analysis tool.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 292
• Est. completion date: September 30, 2019
• Est. primary completion date: September 30, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Diagnosis of PTSD by VA clinicians and acceptance into PE or CPT treatment as part of the PCT

• Veterans of any era

Exclusion Criteria:

• MRI safety contraindications

• Active, uncontrolled medical illness

• Acute suicidality

• Current substance dependence

• Current use of thyroid medication or active hyper/hypothyroidism

• Neurological disorder affecting the CNS Seg stroke, epilepsy, tumorW or penetrating head injury

• Use of PRN within 48 hours of the MRI/EEG

Related Conditions & MeSH terms

• PTSD

Intervention

Other:
• Psychotherapy

Locations

Country	Name	City	State
United States	New Mexico VA Health Care System	Albuquerque	New Mexico
United States	VA Palo Alto Health Care System (VAPAHCS)	Palo Alto	California

Sponsors (2)

Lead Sponsor	Collaborator
Stanford University	New Mexico VA Healthcare System

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Understanding the brain network function-neuroimaging and behavioral with Clinician-Administered PTSD Scale for DSM-5	We will be using CAPS 5	Approximately 3 months

External Links

•   About our lab